Tamer Onder

Has grant

Professor

Koç University
Country flagTurkey

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Discovery and use of novel epigenetic chemical probes in reprogramming and induced pluripotent stem cell generation

Open Date: 2016-10-01

Close Date: 2019-10-01

Grant: Close

Chromatin modifiers in reprogramming

Open Date: 2013-03-01

Close Date: 2017-02-28

Grant: Close

Role of Beta-catenin Signaling in Breast Cancer Invasiveness and Metastasis

Open Date: 2003-10-01

Close Date: 2004-09-01

Articles (12)

Year:

2025

Persistence of JAK2-mutated clones that may undergo clonal evolution and malignant transformation remains a challenge in myeloproliferative neoplasms (MPN), Novel therapeutic approaches to attenuate clonal evolution and progression to blast-phase are therefore urgently needed. LSD1 (KDM1A) inhibitors reduce symptoms and clonal burden in MPN, but whether these compounds may be effective in advanced disease stages remained so far elusive. Using a chromatin-focused CRISPR-Cas9 screen, we identified the histone methyltransferase DOT1L as a synthetic lethal target under pharmacologic LSD1 inhibition. DOT1L knockout impaired cellular fitness, reduced proliferation, and prolonged survival in xenografts. Furthermore, genetic inactivation of DOT1L increased LSD1 inhibitor sensitivity up to 100-fold resulting in cell cycle arrest and apoptosis induction in TP53 mutant blast-phase MPN. Mechanistically, we have identified a novel, non-canonical function of DOT1L which co-occupied LSD1-bound enhancers and contributed to the repression of transcriptional programs independent of its enzymatic activity. DOT1L loss cooperated with LSD1 inhibitors to activate tumor suppressive programs, while pharmacologic inhibition of DOT1Ls catalytic activity failed to elicit comparable effects. These findings indicate that leveraging DOT1L targeting via protein degradation or RNA interference, rather than conventional enzymatic inhibition, could enhance the therapeutic efficacy of LSD1 inhibitors in blast-phase MPN.

Year:

2025

Year:

2025

Triple-negative breast cancer (TNBC) is an aggressive cancer subtype lacking targeted therapies, leaving chemotherapy as the primary treatment option. However, acquired resistance to drugs like paclitaxel (Taxol) poses a significant challenge, often driven by complex genetic and epigenetic changes. Our study identifies bromodomain and PHD finger-containing protein 1 (BRPF1) as a critical epigenetic regulator of Taxol resistance in TNBC cells, linking it to ribosome biogenesis and ABCB1-mediated drug resistance. We developed Taxol-resistant TNBC cell lines using an escalating dose protocol. These cells exhibited sustained resistance to high doses of Taxol, accompanied by significantly elevated expression of ABCB1. Epigenome-wide CRISPR/Cas9 screens revealed that BRPF1 is required for the survival of Taxol-resistant cells. Genetic depletion or pharmacological inhibition of BRPF1 using small-molecule inhibitors sensitized resistant cells to Taxol. RNA sequencing and functional assays demonstrated that BRPF1 loss led to the downregulation of ribosomal biogenesis and translation-related genes, impairing global protein synthesis. Notably, BRPF1 was found to directly bind the ABCB1 promoter, regulating the elevated ABCB1 levels. These findings highlight BRPF1’s dual role in maintaining translation machinery integrity and modulating ABCB1-driven chemoresistance. In conclusion, our work identifies BRPF1 as a novel therapeutic target for combating Taxol resistance in TNBC. Targeting BRPF1 disrupts ribosome biogenesis and reverses ABCB1-mediated drug resistance, offering a promising strategy to overcome chemotherapy failure in aggressive breast cancers. This work was supported by The Scientific and Technological Research Council of Turkey (TUBITAK) 1003-216S461 and 1001-221S419. Citation Format: Ozlem Yedier Bayram, Ahmet Cingöz, Ebru Yilmaz, Ali Cenk Aksu, Beril Esin, Nareg Pinarbaşi-Degirmenci, Ayşe Derya Cavga, Beyza Dedeoglu, Buse Cevatemre, Hamzah Syed, MArtin Philpott, Adam P. Cribbs, Udo Opperman, Nathan A. Lack, Ceyda Açılan Ayhan, Tamer T. Onder, Tugba Bagci Onder. BRPF1 inhibition restores chemosensitivity in triple negative breast cancer via ribosomal pathway modulation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4404.

Year:

2025

Triple-negative breast cancer (TNBC) is a particularly aggressive and frequently recurring form of breast cancer, where chemotherapy is the primary treatment approach. Unfortunately, the development of resistance to chemotherapy poses a considerable challenge, restricting the already limited therapeutic alternatives for recurrent cases. Here, we generated two Taxol-resistant TNBC cell lines with a dose-escalation method to mimic chemotherapy resistance in vitro. These cells exhibited reduced growth rates, altered morphology and evasion of apoptosis. Transcriptome analysis uncovered elevated ABCB1 expression and multidrug-resistant phenotype in these resistant cells. To comprehensively investigate the key epigenetic regulators of Taxol resistance, we conducted chromatin-focused genetic and chemical screens and pinpointed Bromodomain and PHD Finger Containing 1 (BRPF1) as a novel regulator of Taxol resistance. Knockout of BRPF1, the reader protein in the MOZ–MORF histone acetyltransferase complex, but not the other complex members, sensitized resistant cells to Taxol. In addition, BRPF1 inhibitors, PFI-4 and OF-1, in combination with Taxol significantly reduced cell viability. Transcriptome analysis upon BRPF1 loss or inhibition revealed a negative impact on ribosome biogenesis-related gene sets, resulting in a global decrease in protein translation in Taxol-resistant cells. CUT&RUN-qPCR analysis demonstrated that BRPF1 directly binds to the ABCB1 promoter, enhancing its expression toward inducing a multidrug-resistant phenotype. Conversely, knockout or inhibition of BRPF1 leads to decreased ABCB1 expression. Our findings uncover a comprehensive molecular framework, highlighting the pivotal role of epigenetic reader protein BRPF1 in Taxol resistance and providing potential avenues for therapeutic intervention in TNBC.

Year:

2025

Year:

2025

Cellular reprogramming with transient OSKM expression can reverse aging phenotypes, but genetic factor delivery introduces heterogeneous expression, reprogramming-associated stress, and barriers for therapeutic use. Small-molecule chemical reprogramming is an alternative, yet its performance relative to genetic approaches in human cells is unresolved. We directly compared a human-optimized chemical reprogramming protocol with doxycycline-inducible OSKM in progerin-induced aged fibroblasts and primary fibroblasts from donors over 85. Both reprogramming methods reduced senescence, mitochondrial ROS, and age-associated gene expression, with chemical reprogramming matching or exceeding OSKM efficacy. The two approaches, however, followed distinct trajectories. OSKM generated heterogeneous populations, including subsets acquiring pluripotency markers while others retained fibroblast identity. Chemical reprogramming produced uniform CD13-low populations without pluripotency marker induction. OSKM induced acute senescence that required a chase period to resolve, whereas chemical reprogramming lowered senescence during active treatment. In old fibroblasts, chemical reprogramming reversed multiple aging hallmarks while preserving fibroblast identity and avoiding telomerase activation. These results show that human-optimized chemical reprogramming can rejuvenate aged human fibroblasts with comparable efficacy to OSKM while generating more homogeneous outcomes and lower cellular stress, supporting small-molecule approaches as promising avenues for therapeutic rejuvenation.

Year:

2025

Type 1 diabetes can be cured by β–cell replacement in principle, yet recurrent autoimmunity and transplantation barriers rapidly destroy implanted cells. Genome–wide CRISPR screening by Cai et al . highlighted RNLS and HIVEP2 as candidate genes, but their value outside an autoimmune setting is unknown. Here, it was evaluated whether single-gene knockout of RNLS or HIVEP2 could similarly protect β-cell grafts against allo- and xenogeneic rejection. Murine β–TC–6 and human EndoC–βH1 cell lines were genetically edited using CRISPR-Cas9 to knockout RNLS or HIVEP2, and editing efficiencies were confirmed via T7 endonuclease I assay and TIDE analysis. Functional characterization indicated that RNLS deletion modestly impaired glucose-stimulated insulin secretion in murine cells, whereas HIVEP2 deletion showed no functional alterations in either cell line. For in vivo assessment, genetically edited β-cell spheroids were subcutaneously transplanted into CD-1 mice to model allo- (murine β-cells) and xenogeneic (human β-cells) rejection scenarios. Bioluminescence imaging revealed no protective effects of RNLS or HIVEP2 deletion, with grafts from both knockout groups displaying identical rejection kinetics compared to controls. These findings indicate that single-gene deletions of RNLS or HIVEP2 are insufficient for conferring meaningful protection against allo- or xenorejection, highlighting the necessity for combinatorial genome editing strategies or complementary biomaterial-based immunomodulation to achieve effective and sustained β-cell graft survival.

Year:

2025

This protocol collection provides a comprehensive and practical guide for the maintenance, passaging, freezing, and thawing of human pluripotent stem cells (hPSCs). Designed to support reproducibility and transferability, especially among new users, the protocols are informed by extensive experience from established hPSC core facilities. In addition to detailed step-by-step procedures, the collection includes high-quality reference images illustrating healthy hPSC morphology under various culture conditions, as well as visual examples of spontaneous differentiation—serving as critical visual benchmarks for cell quality assessment. The protocols also cover the in-house preparation of Essential 8 (E8) medium and the use of key survival-supporting compounds, including ROCK inhibitors (ROCKi), CEPT cocktail, and CloneR2, ensuring enhanced cell viability during critical manipulations. By consolidating expert-validated practices and making them accessible through a user-friendly format, this collection aims to serve as a foundational resource for laboratories working with hPSCs and to facilitate the standardization of stem cell culture techniques across different research environments.

Year:

2025

Triple-negative breast cancer (TNBC) stands out as a particularly aggressive and frequently recurring form of breast cancer. Due to the absence of hormone receptors, the available treatment avenues are constrained, making chemotherapy the primary approach. Unfortunately, the development of resistance to chemotherapy poses a significant challenge, further restricting the already limited therapeutic alternatives for recurrent cases. Understanding the molecular basis of chemotherapy resistance in TNBC is pivotal for improving treatment outcomes. Here, we generated two different Taxol-resistant TNBC cell lines with a dose-escalation method to mimic chemotherapy resistance in vitro . These cells exhibited hallmark features of resistance, including reduced cell growth, altered morphology, and evasion of apoptosis. Transcriptome analysis uncovered elevated ABCB1 expression and multidrug-resistant phenotype in the resistant cells. To comprehensively investigate the key epigenetic regulators of Taxol resistance, we conducted chromatin-focused genetic and chemical screens and pinpointed Bromodomain and PHD Finger Containing 1 (BRPF1) as a novel regulator of Taxol resistance in TNBC cells. Knockout of BRPF1, the reader protein in the MOZ/MORF histone acetyl-transferase complex, but not the other complex members, sensitized resistant cells to Taxol. Additionally, BRPF1 inhibitors, PFI-4 and OF-1, in combination with Taxol significantly reduced cell viability. Transcriptome analysis upon BRPF1 loss or inhibition revealed a negative impact on ribosome biogenesis-related gene sets, resulting in a global decrease in protein translation in Taxol-resistant cells. Our ChIP-qPCR analysis demonstrated that active BRPF1 directly interacts with the ABCB1 promoter, enhancing its expression towards inducing a multidrug-resistant phenotype. Conversely, knockout or inhibition of BRPF1 leads to decreased ABCB1 expression. This dual mechanism critically sensitizes Taxol-resistant TNBC cells to chemotherapy. Our findings uncover a comprehensive molecular framework, highlighting the pivotal role of epigenetic reader protein BRPF1 in Taxol resistance and providing potential avenues for therapeutic intervention in TNBC.

Year:

2024

Year:

2023

Year:

2023

Collaborators (8)

Paloma Cejas

Head of Innovation/Director

Dana-Farber Cancer Institute

UNITED STATES
View details

Ceyda Acilan

Professor

Koç University

TURKEY
View details

Frederik Damm

Charité - Universitätsmedizin Berlin

GERMANY
View details

İsmail Can Karaoğlu

University of Maastricht

NETHERLANDS
View details

Sonia Kung

-

CANADA
View details

Valeria Fernandez Vallone

Charité - Universitätsmedizin Berlin

GERMANY
View details

Tugba Bagci Onder

Professor

Koç University

TURKEY
View details

Adam P Cribbs

Group leader in systems biology and MRC Career Development Fellow

-

UNITED KINGDOM
View details